Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma

Shinsuke Iida, Takaaki Chou, Shinichiro Okamoto, Hirokazu Nagai, Kiyohiko Hatake, Hirokazu Murakami, Toshiyuki Takagi, Kazuyuki Shimizu, Henry Lau, Kenichi Takeshita, Masaaki Takatoku, Tomomitsu Hotta

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We conducted a multicenter, open-label study to investigate the safety, efficacy, and pharmacokinetics of lenalidomide in Japanese patients with relapsed or refractory multiple myeloma The study was composed of the "monotherapy phase", a dose-escalation phase, to determine the tolerability to single agent lenalidomide and the "combination phase" to determine the safety and obtain preliminary data on the efficacy of lenalidomide plus dexamethasone. The primary end points were the tolerability to 25 mg lenalidomide and safety. Nine and six patients were enrolled in the monotherapy phase and the combination phase, respectively. Since 25 mg of monotherapy treatment did not satisfy the DLT criteria, this dose was employed in the combination phase. The major adverse event was myelosuppression. At the planned interim analysis (median study duration, 26.3 weeks), grade 3 or grade 4 neutropenia was observed with high frequency (66.7%). However, all adverse events observed were clinically manageable. In the combination cohort, the overall response rate (≥PR) was 100%. The pharmacokinetics of lenalidomide showed rapid absorption and elimination after both single and multiple doses. In conclusion, 25 mg of lenalidomide was given safely as a single agent or in combination with dexamethasone in Japanese patients. The good efficacy of the combination therapy was also demonstrated in this study.

Original languageEnglish
Pages (from-to)118-126
Number of pages9
JournalInternational Journal of Hematology
Volume92
Issue number1
DOIs
Publication statusPublished - 2010 Jul

Fingerprint

Multiple Myeloma
Dexamethasone
Safety
Therapeutics
Pharmacokinetics
Neutropenia
lenalidomide

Keywords

  • Dexamethasone
  • Lenalidomide
  • Multiple myeloma
  • Pharmacokinetics

ASJC Scopus subject areas

  • Hematology

Cite this

Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. / Iida, Shinsuke; Chou, Takaaki; Okamoto, Shinichiro; Nagai, Hirokazu; Hatake, Kiyohiko; Murakami, Hirokazu; Takagi, Toshiyuki; Shimizu, Kazuyuki; Lau, Henry; Takeshita, Kenichi; Takatoku, Masaaki; Hotta, Tomomitsu.

In: International Journal of Hematology, Vol. 92, No. 1, 07.2010, p. 118-126.

Research output: Contribution to journalArticle

Iida, S, Chou, T, Okamoto, S, Nagai, H, Hatake, K, Murakami, H, Takagi, T, Shimizu, K, Lau, H, Takeshita, K, Takatoku, M & Hotta, T 2010, 'Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma', International Journal of Hematology, vol. 92, no. 1, pp. 118-126. https://doi.org/10.1007/s12185-010-0624-7
Iida, Shinsuke ; Chou, Takaaki ; Okamoto, Shinichiro ; Nagai, Hirokazu ; Hatake, Kiyohiko ; Murakami, Hirokazu ; Takagi, Toshiyuki ; Shimizu, Kazuyuki ; Lau, Henry ; Takeshita, Kenichi ; Takatoku, Masaaki ; Hotta, Tomomitsu. / Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. In: International Journal of Hematology. 2010 ; Vol. 92, No. 1. pp. 118-126.
@article{8ef1563a902d43a3a7fd0b623ea10fdf,
title = "Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma",
abstract = "We conducted a multicenter, open-label study to investigate the safety, efficacy, and pharmacokinetics of lenalidomide in Japanese patients with relapsed or refractory multiple myeloma The study was composed of the {"}monotherapy phase{"}, a dose-escalation phase, to determine the tolerability to single agent lenalidomide and the {"}combination phase{"} to determine the safety and obtain preliminary data on the efficacy of lenalidomide plus dexamethasone. The primary end points were the tolerability to 25 mg lenalidomide and safety. Nine and six patients were enrolled in the monotherapy phase and the combination phase, respectively. Since 25 mg of monotherapy treatment did not satisfy the DLT criteria, this dose was employed in the combination phase. The major adverse event was myelosuppression. At the planned interim analysis (median study duration, 26.3 weeks), grade 3 or grade 4 neutropenia was observed with high frequency (66.7{\%}). However, all adverse events observed were clinically manageable. In the combination cohort, the overall response rate (≥PR) was 100{\%}. The pharmacokinetics of lenalidomide showed rapid absorption and elimination after both single and multiple doses. In conclusion, 25 mg of lenalidomide was given safely as a single agent or in combination with dexamethasone in Japanese patients. The good efficacy of the combination therapy was also demonstrated in this study.",
keywords = "Dexamethasone, Lenalidomide, Multiple myeloma, Pharmacokinetics",
author = "Shinsuke Iida and Takaaki Chou and Shinichiro Okamoto and Hirokazu Nagai and Kiyohiko Hatake and Hirokazu Murakami and Toshiyuki Takagi and Kazuyuki Shimizu and Henry Lau and Kenichi Takeshita and Masaaki Takatoku and Tomomitsu Hotta",
year = "2010",
month = "7",
doi = "10.1007/s12185-010-0624-7",
language = "English",
volume = "92",
pages = "118--126",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma

AU - Iida, Shinsuke

AU - Chou, Takaaki

AU - Okamoto, Shinichiro

AU - Nagai, Hirokazu

AU - Hatake, Kiyohiko

AU - Murakami, Hirokazu

AU - Takagi, Toshiyuki

AU - Shimizu, Kazuyuki

AU - Lau, Henry

AU - Takeshita, Kenichi

AU - Takatoku, Masaaki

AU - Hotta, Tomomitsu

PY - 2010/7

Y1 - 2010/7

N2 - We conducted a multicenter, open-label study to investigate the safety, efficacy, and pharmacokinetics of lenalidomide in Japanese patients with relapsed or refractory multiple myeloma The study was composed of the "monotherapy phase", a dose-escalation phase, to determine the tolerability to single agent lenalidomide and the "combination phase" to determine the safety and obtain preliminary data on the efficacy of lenalidomide plus dexamethasone. The primary end points were the tolerability to 25 mg lenalidomide and safety. Nine and six patients were enrolled in the monotherapy phase and the combination phase, respectively. Since 25 mg of monotherapy treatment did not satisfy the DLT criteria, this dose was employed in the combination phase. The major adverse event was myelosuppression. At the planned interim analysis (median study duration, 26.3 weeks), grade 3 or grade 4 neutropenia was observed with high frequency (66.7%). However, all adverse events observed were clinically manageable. In the combination cohort, the overall response rate (≥PR) was 100%. The pharmacokinetics of lenalidomide showed rapid absorption and elimination after both single and multiple doses. In conclusion, 25 mg of lenalidomide was given safely as a single agent or in combination with dexamethasone in Japanese patients. The good efficacy of the combination therapy was also demonstrated in this study.

AB - We conducted a multicenter, open-label study to investigate the safety, efficacy, and pharmacokinetics of lenalidomide in Japanese patients with relapsed or refractory multiple myeloma The study was composed of the "monotherapy phase", a dose-escalation phase, to determine the tolerability to single agent lenalidomide and the "combination phase" to determine the safety and obtain preliminary data on the efficacy of lenalidomide plus dexamethasone. The primary end points were the tolerability to 25 mg lenalidomide and safety. Nine and six patients were enrolled in the monotherapy phase and the combination phase, respectively. Since 25 mg of monotherapy treatment did not satisfy the DLT criteria, this dose was employed in the combination phase. The major adverse event was myelosuppression. At the planned interim analysis (median study duration, 26.3 weeks), grade 3 or grade 4 neutropenia was observed with high frequency (66.7%). However, all adverse events observed were clinically manageable. In the combination cohort, the overall response rate (≥PR) was 100%. The pharmacokinetics of lenalidomide showed rapid absorption and elimination after both single and multiple doses. In conclusion, 25 mg of lenalidomide was given safely as a single agent or in combination with dexamethasone in Japanese patients. The good efficacy of the combination therapy was also demonstrated in this study.

KW - Dexamethasone

KW - Lenalidomide

KW - Multiple myeloma

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=77955173933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955173933&partnerID=8YFLogxK

U2 - 10.1007/s12185-010-0624-7

DO - 10.1007/s12185-010-0624-7

M3 - Article

VL - 92

SP - 118

EP - 126

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -